Pfizer Stops Development of Obesity & Diabetes Pill Over Safety Issues 🚫

Pfizer has ceased development of its experimental obesity and diabetes pill, lotiglipron, and will focus on its other oral obesity drug, danuglipron, which has shown promising results in phase two clinical trials. Plans for phase three trials are expected by the end of 2023.